- Start
Presentation
Abyntek Biopharma S.L. is a privately owned biotechnology company that centres its activity in developing, producing and commercializing antigens and antibodies.
A strong investment in R+D+i constitutes one of the fundamental values on which the business strategy of Abyntek is based.
The R+D+i activities of Abyntek focus on two main areas:
- The development of new technologies to produce monoclonal antibodies.
- The development of diagnostic and prognostic products, as well as products to predict the response to treatment and for the treatment of lung diseases.
Abyntek is an integral part of the Progenika Biopharma S.A. and Proteomika S.L. group of companies.